Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability.
Gastrointestinal homeostasis
Mucosal barrier function
Pre-clinical model
Toll-like receptor 4
Ussing chamber
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
04
2021
accepted:
23
08
2021
entrez:
27
1
2022
pubmed:
28
1
2022
medline:
28
1
2022
Statut:
epublish
Résumé
Toll-like receptor 4 (TLR4) is a highly conserved immunosurveillance protein of innate immunity, displaying well-established roles in homeostasis and intestinal inflammation. Current evidence shows complex relationships between TLR4 activation, maintenance of health, and disease progression; however, it commonly overlooks the importance of site-specific TLR4 expression. This omission has the potential to influence translation of results as previous evidence shows the differing and distinct roles that TLR4 exhibits are dependent on its spatiotemporal expression. An intestinal epithelial TLR4 conditional knockout (KO) mouse line ( There was no impact of the intestinal epithelial TLR4 KO, with no differences in (1) tissue resistance-ileum (mean ± standard error of mean [SEM]): WT 22 ± 7.2 versus These data have 2 important implications. First, these data refute the assumption that epithelial TLR4 exerts physiological control of intestinal physiology and immunity in health. Second, and most importantly, these data support the use of the
Identifiants
pubmed: 35083285
doi: 10.1159/000519200
pii: iid-0006-0199
pmc: PMC8739639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
199-209Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
BMC Immunol. 2008 Nov 24;9:69
pubmed: 19025640
Pathophysiology. 2014 Feb;21(1):81-93
pubmed: 24365655
Front Immunol. 2014 Aug 12;5:386
pubmed: 25161655
Mol Ther Nucleic Acids. 2018 Jun 1;11:159-169
pubmed: 29858051
Sci Rep. 2017 Mar 03;7:43337
pubmed: 28256612
J Biol Chem. 2002 Sep 6;277(36):33275-83
pubmed: 12065599
PLoS One. 2012;7(8):e42777
pubmed: 23028414
Nat Rev Immunol. 2010 Feb;10(2):131-44
pubmed: 20098461
Braz J Infect Dis. 2016 Mar-Apr;20(2):193-204
pubmed: 26775799
Ann Transl Med. 2019 Dec;7(23):713
pubmed: 32042729
Front Pharmacol. 2017 Jun 08;8:350
pubmed: 28642706
Blood. 2011 Jun 16;117(24):6542-51
pubmed: 21493800
J Immunol. 2006 Apr 1;176(7):4275-83
pubmed: 16547265
Mol Cancer Ther. 2016 Nov;15(11):2767-2779
pubmed: 27550942
J Immunol. 2015 Feb 15;194(4):1983-95
pubmed: 25589072
Gastroenterology. 2012 Sep;143(3):708-718.e5
pubmed: 22796522
Cancer Biol Ther. 2014 Feb;15(2):236-44
pubmed: 24316664
EMBO Rep. 2012 Aug;13(8):684-98
pubmed: 22801555
J Nutr. 1996 Oct;126(10):2519-30
pubmed: 8857513
Curr Opin Cell Biol. 2004 Apr;16(2):140-5
pubmed: 15196556
Mol Cancer Ther. 2016 Jun;15(6):1376-86
pubmed: 27197307
Cancer Chemother Pharmacol. 2017 Feb;79(2):431-434
pubmed: 28011980
Pediatr Neonatol. 2018 Oct;59(5):464-473
pubmed: 29276042
Front Immunol. 2014 Jul 10;5:316
pubmed: 25071777
Physiol Rep. 2015 Feb 12;3(2):
pubmed: 25677543
Neurogastroenterol Motil. 2015 Sep;27(9):1258-66
pubmed: 26053401
Infect Immun. 2016 Jan 11;84(3):798-810
pubmed: 26755160
Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G171-G193
pubmed: 27908847